<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03503266</url>
  </required_header>
  <id_info>
    <org_study_id>MT-7117-E02</org_study_id>
    <secondary_id>2017-004549-25</secondary_id>
    <nct_id>NCT03503266</nct_id>
  </id_info>
  <brief_title>Mass Balance Study With MT-7117</brief_title>
  <acronym>MT-7117 MB</acronym>
  <official_title>An Open-label, Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-MT-7117 After a Single Oral Dose to Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Development America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Development America, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-centre, open-label, mass balance study in healthy male subjects utilising a&#xD;
      single oral dose of [14C] MT 7117.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 23, 2018</start_date>
  <completion_date type="Actual">May 11, 2018</completion_date>
  <primary_completion_date type="Actual">May 11, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open Label</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax - maximum observed plasma concentration (plasma and whole blood)</measure>
    <time_frame>at pre-dose and up to 168 hours post-dose. If collection is extended up to Day 14: at up to 312 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>tmax - time at which Cmax occurs (plasma and whole blood)</measure>
    <time_frame>at pre-dose and up to 168 hours post-dose. If collection is extended up to Day 14: at up to 312 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0 t - area under the plasma concentration time curve from time zero to the last measurable concentration (plasma and whole blood)</measure>
    <time_frame>at pre-dose and up to 168 hours post-dose. If collection is extended up to Day 14: at up to 312 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ - area under the plasma concentration-time curve from time zero to infinity (plasma and whole blood)</measure>
    <time_frame>at pre-dose and up to 168 hours post-dose. If collection is extended up to Day 14: at up to 312 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t½ - apparent terminal elimination half-life (plasma and whole blood)</measure>
    <time_frame>at pre-dose and up to 168 hours post-dose. If collection is extended up to Day 14: at up to 312 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Kel - terminal elimination rate constant (plasma and whole blood)</measure>
    <time_frame>at pre-dose and up to 168 hours post-dose. If collection is extended up to Day 14: at up to 312 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F - apparent clearance (plasma and whole blood)</measure>
    <time_frame>at pre-dose and up to 168 hours post-dose. If collection is extended up to Day 14: at up to 312 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>VZ/F - apparent volume of distribution (plasma and whole blood)</measure>
    <time_frame>at pre-dose and up to 168 hours post-dose. If collection is extended up to Day 14: at up to 312 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total radioactivity in urine and faeces</measure>
    <time_frame>Day -1 and up to 168 hours post-dose. If collection is extended up to Day 14: up to 312 hours post-dose.</time_frame>
    <description>Ae (urine), Ae (faeces) and Ae (total): amount excreted and cumulative amount excreted in urine, faeces and total (urine and faeces combined).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total radioactivity in urine and faeces</measure>
    <time_frame>Day -1 and up to 168 hours post-dose. If collection is extended up to Day 14: up to 312 hours post-dose.</time_frame>
    <description>%Ae (urine), %Ae (faeces) and %Ae (total): amount excreted and cumulative amount excreted in urine, faeces and total (urine and faeces combined) expressed as a percentage of the dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as measured by incidence of adverse events (AEs) and serious AEs</measure>
    <time_frame>Up to 14 Days after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>[14C] MT-7117</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14-C MT-7117</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C] MT-7117</intervention_name>
    <description>14-C MT-7117</description>
    <arm_group_label>[14C] MT-7117</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Able to provide written informed consent to participate in this study after reading&#xD;
             the participant information sheet and Informed Consent Form, and after having the&#xD;
             opportunity to discuss the study with the Investigator or designee.&#xD;
&#xD;
          -  2. Caucasian male subjects aged 30 to 65 years (inclusive) at Screening.&#xD;
&#xD;
          -  3. Healthy and free from illness or disease as determined by medical history, physical&#xD;
             examination, electrocardiogram (ECG), vital signs, laboratory and other tests at&#xD;
             Screening and Day -1, unless deemed not clinically significant by the Investigator or&#xD;
             designee.&#xD;
&#xD;
          -  4. Body weight of 60 to 110 kg (inclusive) and a body mass index (Quetelet index)&#xD;
             ranging from 18 to 32 kg/m2 (inclusive) at Screening and Day -1.&#xD;
&#xD;
          -  5. Vital signs within the following ranges at Screening and Day -1:&#xD;
&#xD;
               -  Systolic blood pressure: 90 to 140 mmHg&#xD;
&#xD;
               -  Diastolic blood pressure: 50 to 90 mmHg&#xD;
&#xD;
          -  6. Subjects and partners agree to use contraception throughout the study, as defined&#xD;
             in the Protocol body.&#xD;
&#xD;
          -  7. Able to understand, in the Investigator's opinion, the nature of the study and any&#xD;
             risks involved in participation and willing to cooperate and comply with the Protocol&#xD;
             restrictions and requirements.&#xD;
&#xD;
          -  8. Regular daily bowel movements (i.e., production of at least one stool per day).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Presence or history of severe adverse reaction or allergy to any medicinal product&#xD;
             that is of clinical significance.&#xD;
&#xD;
          -  2. Participated in more than three clinical studies of a new chemical entity in the&#xD;
             previous year or participated in a clinical study of any IMP within 12 weeks or five&#xD;
             half-lives (whichever is longer) before the administration of IMP in this clinical&#xD;
             study.&#xD;
&#xD;
          -  3. Consumption of any food-supplements, prescribed or over the counter medicine&#xD;
             (including herbal and dietary supplements, such as St. John's Wort) during the 7 days&#xD;
             (or 14 days if the medicine is a potential enzyme inducer) or five half-lives&#xD;
             (whichever is longer) before the administration of IMP and during the study, unless in&#xD;
             the opinion of the Sponsor and the Investigator, the medication will not interfere&#xD;
             with the objectives of the study or compromise the subject's safety (Note: The use of&#xD;
             acetaminophen [2 g/day for up to 3 consecutive days] will be permitted from Screening&#xD;
             and during the study).&#xD;
&#xD;
          -  4. Clinically significant (in the opinion of the Investigator) endocrine, thyroid,&#xD;
             hepatic (including Gilbert's syndrome), respiratory, gastrointestinal or renal&#xD;
             disease, diabetes mellitus (type I and II), coronary heart disease, hypertension, or&#xD;
             significant history of any psychiatric/psychotic disorder (including anxiety,&#xD;
             depression and reactive depression).&#xD;
&#xD;
          -  5. Clinically relevant abnormal medical history, physical findings or laboratory&#xD;
             values at Screening or Day -1 that could interfere with the objectives of the study or&#xD;
             the safety of the subject, as judged by the Investigator.&#xD;
&#xD;
          -  6. Subjects with aspartate aminotransferase or alanine aminotransferase ≥2 x upper&#xD;
             limit of normal or bilirubin above reference range at Screening or Day -1, confirmed&#xD;
             by a repeat test at each visit.&#xD;
&#xD;
          -  7. Has a positive hepatitis B surface antigen, hepatitis B core antibody, hepatitis C&#xD;
             virus antibody, or human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2)&#xD;
             result at Screening.&#xD;
&#xD;
          -  8. Clinically significant abnormal 12-lead ECG findings, including subjects with&#xD;
             corrected QT interval using Fridericia's formula (QTcF) of &gt;450 ms, or presence of&#xD;
             atrial fibrillation or other significant arrhythmia at Screening or Day -1, confirmed&#xD;
             by repeat assessment.&#xD;
&#xD;
          -  9. Any surgical or medical condition which might significantly alter the absorption,&#xD;
             distribution, metabolism or excretion of drugs or which may jeopardise the subject in&#xD;
             case of participation in the study. The Investigator should be guided by evidence of&#xD;
             any of the following:&#xD;
&#xD;
               -  history of inflammatory bowel syndrome, gastritis, ulcers, gastrointestinal or&#xD;
                  rectal bleeding;&#xD;
&#xD;
               -  history of major gastrointestinal tract surgery such as gastrectomy,&#xD;
                  gastroenterostomy or bowel resection;&#xD;
&#xD;
               -  history or clinical evidence of pancreatic injury or pancreatitis.&#xD;
&#xD;
          -  10. Excessive consumption of food or drink containing caffeine, including coffee, tea,&#xD;
             cola, energy drinks or chocolates (&gt;5 cups of coffee or equivalent per day).&#xD;
&#xD;
          -  11. Consumption of food or drink containing grapefruit, poppy seeds or Seville oranges&#xD;
             from 7 days before the administration of the IMP.&#xD;
&#xD;
          -  12. Presence or history (in the last 2 years) of alcohol abuse or weekly alcohol&#xD;
             intake of more than 28 units (224 g) or a positive urine or breath alcohol test at&#xD;
             Screening or Day 1. One unit (8 g) is equivalent to a ½ pint (280 mL) of beer, 1&#xD;
             measure (25 mL) of spirits or 1 small glass (125 mL) of wine.&#xD;
&#xD;
          -  13. Presence or history of drug abuse (as defined by Diagnostic and Statistical Manual&#xD;
             of Mental Disorders [DSM-V] criteria) or a positive urine test for drugs of abuse at&#xD;
             Screening or Day -1.&#xD;
&#xD;
          -  14. Donation of one or more units of blood (450 mL) within 3 months before the&#xD;
             administration of the IMP, or plasma within 7 days prior to Screening, or platelets&#xD;
             within 6 weeks prior to Screening or the intention to donate blood within 3 months&#xD;
             after the final study visit.&#xD;
&#xD;
          -  15. Use of tobacco or nicotine-containing products (snuff, chewing tobacco, cigars,&#xD;
             pipes, e cigarettes or nicotine replacement products) within the 3 month period prior&#xD;
             to administration of IMP, during the confinement period and until the final study&#xD;
             visit, or positive urine cotinine test at Screening or Day -1.&#xD;
&#xD;
          -  16. Heavy physical training or excessive exercise (e.g., long distance running, weight&#xD;
             lifting or any physical activity to which the subject is not accustomed) from 7 days&#xD;
             before the administration of IMP, during the participation in the study and for 7 days&#xD;
             prior to any outpatient visit.&#xD;
&#xD;
          -  17. Family history of long QT syndrome or Torsades de Pointes.&#xD;
&#xD;
          -  18. Subjects with poor peripheral venous access.&#xD;
&#xD;
          -  19. Subjects who had a major surgical procedure or significant traumatic injury within&#xD;
             14 days prior to Day -1, or anticipation of the need for major surgery during the&#xD;
             study period.&#xD;
&#xD;
          -  20. Subjects with creatinine clearance &lt;60 mL/minute (calculated using Cockcroft-Gault&#xD;
             formula) at Screening.&#xD;
&#xD;
          -  21. History of irritable bowel syndrome or other manifestation of abnormal bowel habit&#xD;
             (e.g., diarrhoea, constipation).&#xD;
&#xD;
          -  22. Previous exposure to MT-7117 before the administration of IMP in this study.&#xD;
&#xD;
          -  23. Radiation exposure, including that from the present study, excluding background&#xD;
             radiation but including diagnostic x rays and other medical exposures, exceeding 5 mSv&#xD;
             in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker,&#xD;
             as defined in the Ionising Radiation Regulations 1999, shall participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>General Manager</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Europe Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Centre</name>
      <address>
        <city>United Kingdom</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>March 18, 2018</study_first_submitted>
  <study_first_submitted_qc>April 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2018</study_first_posted>
  <last_update_submitted>June 8, 2018</last_update_submitted>
  <last_update_submitted_qc>June 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mass Balance Study with MT-7117</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

